Navigation Links
Researchers at IRB Barcelona discover one of the mechanisms that prevents the spread of colon cancer
Date:9/30/2007

The first step in the development of colon cancer is the formation of benign tumours, called adenomas, in the intestine. Over time, these tumours may progress to produce colon cancer if they undergo a series of mutations and genetic alterations. Researchers at IRB Barcelona under the direction of Eduard Batlle, ICREA researcher and head of IRB Barcelonas Oncology Programme, have discovered a new mechanism by which the benign tumour cells receive instructions to grow in confined compartments, and no to invade other areas of the tissue. The description of this new tumour suppression mechanism is reported in the scientific journal Nature Genetics.

The scientists observed that adenomatous tumour cells have special surface receptors, called EphB2 and EphB3, which detect the presence of certain ligands in the healthy tissue that surround them. These receptors and their ligands serve to organize the structure of intestinal tissue. Thanks to the activity of EphB2 and EphB3, the tumour cells are forced to listen to the signals that they receive from their environment. These signals make the benign tumours grow in a confined space, from which they are unable to spread. We knew that these receptors worked as tumour suppressors, but we did not know how. Now we have been able to observe that they compartmentalize the tumour, thereby preventing its spread, explains Batlle.

Until the tumour cells learn to deactivate these receptors, they cannot invade other tissue outside the compartment. Batlle goes on to say, as the tumour cells progress to become malignant, their genetic programme is refined and they remove the signals that block their growth, including these two receptors, which impose positional information.

This study explains one of the key mechanisms of how a benign tumour transforms into a malignant one during the onset of colon cancer. Using experiments performed with animal models and in vitro cells, the scientists determined that the loss of compartmentalization, that is to say, the loss-of-function of these two receptors, is one of the vital factors in the development of adenoma-derived colon cancer.

It is estimated that between 30 and 50% of people over 60 years of age may develop one of these benign adenomas. Cancer of the colon ranks first in the list of the most common cancers in Spain, with more than 25,000 causes diagnosed each year. Last year alone, more than half a million people worldwide died as a result of this disease.


'/>"/>

Contact: Sonia Armengou
sonia.armengou@irbbarcelona.org
34-934-037-255
Institute for Research in Biomedicine (IRB Barcelona)
Source:Eurekalert

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers identify the early makers of Neonatal Sepsis
4. OHSU Researchers Announce New Discovery
5. Researchers Identify Gene Connected To Bipolar Disorder
6. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
7. Researchers trick Alzheimers Enzyme
8. Researchers find new HIV hiding place
9. Gene researchers make Malaria-resistant mosquito
10. New Hair in 15 Days Could Now Be A Possibility Say Researchers
11. Researchers developed world’s smallest toothbrus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... First Choice ... celebrating the one year anniversary of its Houston-Fallbrook facility. , “We are ... Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has been a ...
(Date:9/22/2017)... ... ... “Letters From Home”: a moving compilation of letters that remind readers of the ... is the creation of published author, John Allred, a passionate leader of ministry to ... who has traveled and ministered on four continents. , “It is my hope and ...
(Date:9/21/2017)... , ... September 21, 2017 , ... With ProSlideshow Portrait ... and easy to do. Users can select from up to two layers of subject ... click of a mouse all within Final Cut Pro X. , With ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... learn with Infinity Behavioral Health Services for professionals in the addiction treatment industry ... Payer Audit . , Insurance companies and state and federal governments are ...
(Date:9/21/2017)... ... September 21, 2017 , ... Bill Howe Plumbing’s mission is to create an ... to the community. For over 37 years, they have operated with their mission at ... in San Diego. They were chosen as the Best San Diego plumber in ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: